Concepedia

Author

Ángel Segura

Hospital Universitari i Politècnic La FeORCID

Also Known As

A Paredes Segura, A Segura, A. Segura, Angel Segura, Isabel Sevilla, Segura, A., Segura, Ángel, Á. Segura, Ángel Segura, Ángel Segura Huerta

86

Publications

1.7K

Citations

20

H-Index

55

Concepts

All Affiliations

Hospital Universitari i Politècnic La FeHospital General Universitario de ElcheVall d'Hebron Hospital UniversitariHospital Universitario Miguel ServetHospital Universitario de Canarias
ÁS

About

Ángel Segura is an author at Hospital Universitari i Politècnic La Fe specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

16

774

2

Health Sciences

3

3

68

3

Public Health

2

2

320

4

Engineering

1

1

27

5

Cell Biology

1

1

27

Ángel Segura

×

29

Publications

1.4K

Citations

18

H-Index

YearCitations

An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer

Ángel Segura, J Marín Pardo, Carlos Jara,

Clinical Nutrition

2005

242

New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis

Laura Valle, Eva Hernández‐Illán, Fernando Bellido,

Human Molecular Genetics

2014

154

De Novo Internal Neoplasms after Liver Transplantation: Increased Risk and Aggressive Behavior in Recent Years?

Salvador Benlloch, Marina Berenguer, M. Prieto,

American Journal of Transplantation

2004

133

Sorafenib in metastatic thyroid cancer

Jaume Capdevila, L. Iglesias, Irene Halperín,

Endocrine Related Cancer

2012

108

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

Barbara Nuñez-Valdovinos, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca,

The Oncologist

2018

90

Prevalence of germline MUTYH mutations among Lynch-like syndrome patients

Adela Castillejo, Gardenia Vargas‐Parra, M.I. Castillejo,

European Journal of Cancer

2014

78

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Marta Martín-Richard, Bartomeu Massutí, Eva Margarita Pineda,

BMC Cancer

2013

70

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca,

Journal of Clinical Oncology

2019

69

Pulmonary Fibrosis Induced by Cyclophosphamide

Ángel Segura, Ana Yuste, Ana C Cercós,

Annals of Pharmacotherapy

2001

57

1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Jaume Capdevila, Àlex Teulé, Carlos López,

Annals of Oncology

2020

47

Page 1